| 6KPP: reference: Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design., Wang T, Wu C, Wang C, Zhang G, Arnst KE, Yao Y, Zhang Z, Wang Y, Pu D, Li W, Biochem Biophys Res Commun. 2020 Feb 18. pii: S0006-291X(20)30008-5. doi:, 10.1016/j.bbrc.2019.12.083. PMID: 32085900 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).